William Sutherland

Gene Mannheimer

Anthony Vendetti

Bradford Seagraves

Carl Byrnes

Joshua Cohen

Thomas McGovern

Tom McGovern

- Pomerantz LLP has filed a **class action lawsuit** against Nutex Health Inc. and certain officers, covering the period from **August 8, 2024, to August 14, 2025**.  **[1479681_20251003DC87778:0]**  Investors have until **October 21, 2025**, to ask the Court to appoint them as Lead Plaintiff.  **[1479681_20251003DC87778:0]** 
- The lawsuit alleges that Nutex made materially false and misleading statements, including that its revenues were unsustainable due to a **fraudulent arbitration scheme with HaloMD** and that it overstated its remediation of **material weaknesses in internal controls**.  **[1479681_20251003DC87778:2]** 
- Following a Blue Orca Report alleging fraud, Nutex's stock price fell **$11.18 per share (10.05%)** on July 22, 2025, and an additional **$18.22 per share (16.39%)** on August 15, 2025, after the company failed to rebut the allegations.  **[1479681_20251003DC87778:2]** **[1479681_20251003DC87778:3]** 
- Nutex announced a **delay in filing its Q2 2025 Form 10-Q** and its Audit Committee concluded that certain previously issued financial statements should be **restated** due to improper accounting of stock-based compensation obligations as equity instead of liabilities.  **[1479681_20251003DC87778:2]** **[1479681_20251003DC87778:3]**

Class Action Lawsuit Filed Against Nutex Health

- **Nutex Health (NUTX)** operates two main divisions: a micro-hospital business, which generates **95% of its revenue** and includes **24 locations** across 11 states, with plans to reach **27 locations by the end of 2025**; and a smaller population health division.  **[1479681_2162620_1]** 
- The company experienced a significant financial setback in **2022** due to the **No Surprises Act**, which led to a **35% drop in revenue** and reduced adjusted EBITDA from **$145 million to $12 million**.  **[1479681_2162620_5]** 
- By the end of **2024**, Nutex Health had largely recovered its revenue and margins to near pre-No Surprises Act levels, achieved through increased patient volume, higher inpatient admissions, and successful utilization of **arbitration**, winning **85% of cases** since **July 2024**.  **[1479681_2162620_5]** **[1479681_2162620_6]**  This positive trend is reported to be continuing into **Q1 and Q2 2025**.  **[1479681_2162620_6]** 
- Growth opportunities for the company include building **3 to 5 new micro-hospitals annually**, with **15 projects** currently in development and a pipeline extending into **2027 and 2028**, as well as acquiring existing Independent Physician Associations (IPAs).  **[1479681_2162620_4]** **[1479681_2162620_5]**

Nutex Health Discusses Business Model and Financial Recovery at Investor Conference

- Faruqi & Faruqi, LLP is investigating potential securities claims against **Nutex Health Inc. (NUTX)**, alleging the company made false and/or misleading statements and failed to disclose information.  **[1479681_ee6a585751184123b8c1514b915448c6_1]** 
- The allegations include that Nutex's vendor, HaloMD, engaged in a **"coordinated fraudulent scheme"** to defraud insurance companies, leading to unsustainable revenues, and that Nutex overstated its ability to remediate material weaknesses in internal controls over financial reporting.  **[1479681_ee6a585751184123b8c1514b915448c6_1]** 
- Investors who suffered losses between **August 8, 2024, and August 15, 2025**, are encouraged to contact the firm, with a **deadline of October 21, 2025**, to seek the role of lead plaintiff.  **[1479681_ee6a585751184123b8c1514b915448c6_0]** **[1479681_ee6a585751184123b8c1514b915448c6_1]** 
- Nutex's stock price experienced significant drops: **10.05%** on **July 22, 2025**, following a Blue Orca Capital short report, and another **16.39%** on **August 15, 2025**, after the company announced a delay in filing its Form 10-Q for Q2 2025.  **[1479681_ee6a585751184123b8c1514b915448c6_1]** **[1479681_ee6a585751184123b8c1514b915448c6_2]**

Nutex Health Faces Securities Class Action Investigation

- Pomerantz LLP has filed a class action lawsuit against **Nutex Health Inc. (NUTX)** and certain officers, covering securities purchased between **August 8, 2024, and August 14, 2025**, alleging violations of federal securities laws.  **[1479681_20250928DC83425:0]** 
- The lawsuit claims that Nutex's significant revenue increase in 2024, largely attributed to its arbitration strategy with **HaloMD**, was based on a **coordinated fraudulent scheme** to defraud insurance companies, making these revenues unsustainable.  **[1479681_20250928DC83425:1]** **[1479681_20250928DC83425:2]** 
- Following a short report by Blue Orca Capital on **July 22, 2025**, alleging this fraud, Nutex's stock price fell **10.05%** to **$100.01** per share.  **[1479681_20250928DC83425:2]** 
- Nutex subsequently announced a **delay in filing its Q2 2025 Form 10-Q** on **August 14, 2025**, and on **August 21, 2025**, filed an 8-K indicating that previously issued financial statements **"should be restated"** due to misclassification of non-cash obligations and included a **Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard**.  **[1479681_20250928DC83425:2]** **[1479681_20250928DC83425:3]**

Nutex Health Faces Class Action Lawsuit and Announces Financial Restatement

- Faruqi & Faruqi, LLP is investigating **Nutex Health Inc. (NASDAQ: NUTX)** for a federal securities class action, alleging the company made false and misleading statements and failed to disclose information between **August 8, 2024, and August 15, 2025**.  **[1479681_20250924NY81792:0]** 
- The complaint claims Nutex's revenues from its **HaloMD** relationship were unsustainable due to alleged fraudulent schemes against insurance companies, and that the company overstated its remediation of material weaknesses in internal controls, particularly regarding stock-based compensation obligations.  **[1479681_20250924NY81792:0]** 
- Nutex's stock price fell **10.05%** on **July 22, 2025**, after a **Blue Orca Capital short report**, and an additional **16.39%** on **August 15, 2025**, following the company's delay in filing its Q2 2025 Form 10-Q and failure to rebut the report's allegations.  **[1479681_20250924NY81792:0]** 
- The deadline for investors to seek lead plaintiff status in the class action is **October 21, 2025**.  **[1479681_20250924NY81792:0]**

Nutex Health Faces Federal Securities Class Action Investigation

- Pomerantz LLP has filed a class action lawsuit against **Nutex Health Inc.** and certain officers, on behalf of investors who purchased securities between **August 8, 2024, and August 14, 2025**.  **[1479681_20250923DC80147:0]** 
- The lawsuit alleges that Nutex made materially false and misleading statements, particularly concerning the sustainability of revenues generated through its engagement with **HaloMD** in the independent dispute resolution (IDR) process, which was accused of engaging in a fraudulent scheme.  **[1479681_20250923DC80147:2]** 
- It is also alleged that Nutex overstated its ability to remediate material weaknesses in its internal controls over financial reporting, leading to the improper classification of stock-based compensation obligations as equity rather than liabilities.  **[1479681_20250923DC80147:2]** 
- Following a **Blue Orca Capital short report** on **July 22, 2025**, Nutex's stock price fell **$11.18 per share, or 10.05%**.  **[1479681_20250923DC80147:2]**  The company subsequently announced a **delay in filing its Form 10-Q for Q2 2025** and that its Audit Committee concluded certain previously issued financial statements should be **restated** due to accounting errors related to stock-based compensation.  **[1479681_20250923DC80147:2]** **[1479681_20250923DC80147:3]** 
- Nutex's stock price experienced a further decline of **$18.22 per share, or 16.39%**, on **August 15, 2025**, after the company failed to meaningfully rebut the allegations in the Blue Orca Report.  **[1479681_20250923DC80147:3]**

Nutex Health Inc. Faces Class Action Lawsuit and Financial Restatement

- Nutex Health Inc. **(NASDAQ: NUTX)** is facing a class-action lawsuit alleging a deceptive billing strategy involving third-party firm HaloMD to artificially boost financial results through ineligible insurance claims and exploitation of the insurance arbitration process.  **[1479681_20250919SF77538:0]** 
- The lawsuit claims Nutex misrepresented its progress in addressing internal control deficiencies, specifically misclassifying stock-based compensation obligations as equity rather than liabilities, and that its Audit Committee determined certain prior financial statements required **restatement** due to incorrectly classified hospital development obligations.  **[1479681_20250919SF77538:0]** 
- The allegations gained traction after a short-seller report by Blue Orca Capital on **July 22, 2025**, which led to Nutex shares dropping over **10%**.  **[1479681_20250919SF77538:0]** 
- On **August 14, 2025**, Nutex announced a delay in submitting its Form 10-Q, citing "non-cash accounting adjustments," causing its shares to plunge **16.39%** the following day, closing at **$92.91**.  **[1479681_20250919SF77538:0]** 
- The class period for the lawsuit is **August 8, 2024, to August 14, 2025**, with the lead plaintiff deadline set for **October 21, 2025**.  **[1479681_20250919SF77538:0]**

Nutex Health Faces Class-Action Lawsuit Over Alleged Deceptive Billing and Financial Misstatements

- Faruqi & Faruqi, LLP is investigating potential claims against **Nutex Health Inc. (NUTX)** and reminds investors of a federal securities class action lawsuit with a lead plaintiff deadline of **October 21, 2025**.  **[1479681_20250918NY77249:0]** 
- The complaint alleges that Nutex made false or misleading statements, including issues related to **HaloMD's arbitration results**, unsustainable revenues, and **material weaknesses in internal controls over financial reporting** concerning stock-based compensation obligations.  **[1479681_20250918NY77249:0]** 
- This class action follows a **July 22, 2025**, Blue Orca Capital short report and Nutex's subsequent **August 14, 2025**, announcement of a delay in filing its **Q2 2025 Form 10-Q** due to accounting adjustments for stock-based compensation.  **[1479681_20250918NY77249:0]** 
- Nutex's stock price fell **10.05%** on **July 22, 2025**, and an additional **16.39%** on **August 15, 2025**, following these events.  **[1479681_20250918NY77249:0]**

Nutex Health Faces Securities Class Action Lawsuit

- Pomerantz LLP has filed a class action lawsuit against **Nutex Health Inc.** and certain officers, covering the period from **August 8, 2024, to August 14, 2025**, for alleged violations of federal securities laws.  **[1479681_20250918DC75019:0]** 
- The lawsuit alleges that Nutex made materially false and misleading statements, including that revenues from its third-party IDR vendor, **HaloMD**, were unsustainable due to a coordinated scheme to defraud insurance companies.  **[1479681_20250918DC75019:2]** 
- It is also alleged that the Company overstated its ability to remediate material weaknesses in internal controls, leading to the improper classification of stock-based compensation obligations as equity rather than liabilities.  **[1479681_20250918DC75019:2]** 
- Following a short report by Blue Orca Capital on **July 22, 2025**, Nutex's stock price fell **10.05%** that day and an additional **16.39%** on **August 15, 2025**, after the company delayed its Q2 2025 Form 10-Q filing.  **[1479681_20250918DC75019:2]** **[1479681_20250918DC75019:3]** 
- On **August 21, 2025**, Nutex announced that certain previously issued financial statements would need to be **restated** due to the incorrect treatment of non-cash obligations as equity instead of liabilities.  **[1479681_20250918DC75019:3]**

Nutex Health Inc. Faces Class Action Lawsuit

- **Nutex Health Inc. (NASDAQ: NUTX)** is facing a **class-action lawsuit** alleging a deceptive billing strategy, collaborating with **HaloMD** to submit ineligible insurance claims and exploit the arbitration process to artificially boost financial results.  **[1479681_20250916SF75323:0]** 
- The allegations gained traction after a **Blue Orca Capital short-seller report** on **July 22, 2025**, which accused HaloMD of a "fraudulent scheme" and led to a **10%+ drop** in Nutex shares.  **[1479681_20250916SF75323:0]** 
- Nutex is also accused of misrepresenting progress in addressing internal control deficiencies and, on **August 21, 2025**, disclosed that its **Audit Committee determined prior financial statements required restatement** due to incorrectly classified hospital development obligations.  **[1479681_20250916SF75323:0]** 
- The **Class Period** for the lawsuit is **August 8, 2024 – August 14, 2025**, with the **Lead Plaintiff Deadline** set for **October 21, 2025**.  **[1479681_20250916SF75323:0]**